Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 9, Number 9—September 2003


Ehrlichia chaffeensis Infections among HIV-infected Patients in Human Monocytic Ehrlichiosis–Endemic Area

Thomas R. Talbot*Comments to Author , James A. Comer†, and Karen C. Bloch*
Author affiliations: *Vanderbilt University School of Medicine, Nashville, Tennessee, USA; †Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article


Baseline characteristics of study cohort of HIV-positive persons residing in Tennesseea

Characteristic N (% or range)
Age (mean, y)
38.8 (21–75)

107 (80.5%)
26 (19.5%)
Baseline CD4 count (median, cells/mm3)
370 (6–1,200)
Baseline viral load (median, copies/dL)
1,003 (<400–>750,000)
On prophylaxis

122 (91.7%)
OI prophylaxis
70 (52.6%)
PCP prophylaxisb
66 (49.6%)
MAC prophylaxisc
31 (23.3%)
Average number of clinic visitsd
4.75 (1–13)
Treated with antibiotic therapyd,e
40/133 (30.1%)
Treated with doxycyclined
14/133 (10.5%)
Hospitalizedd 7/133 (5.3%)

          aHAART, highly active antiretroviral therapy; OI, opportunistic infection; PCP, Pneumocystis carinii pneumonia; MAC, Mycobacterium avium complex.
          bPCP prophylaxis: use of trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine therapy.
          cMAC prophylaxis: use of azithromycin or clarithromycin therapy.
          dDuring the study period.
          eAntibiotics used to treat the ongoing clinical symptoms; persons taking antibiotic therapy specifically for OI prophylaxis alone were not included.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO